ZOLOFT Drug Patent Profile

When do Zoloft patents expire, and what generic alternatives are available?

Zoloft is a drug marketed by Viatris and is included in two NDAs.

The generic ingredient in ZOLOFT is sertraline hydrochloride. There are twenty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the sertraline hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zoloft

A generic version of ZOLOFT was approved as sertraline hydrochloride by STRIDES PHARMA on June 30^th, 2006.

Summary for ZOLOFT

US Patents:	0
Applicants:	1
NDAs:	2

Paragraph IV (Patent) Challenges for ZOLOFT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZOLOFT	Tablets	sertraline hydrochloride	150 mg and 200 mg	019839	1	2005-11-09
ZOLOFT	Oral Concentrate	sertraline hydrochloride	20 mg/mL	020990	1	2003-12-09

US Patents and Regulatory Information for ZOLOFT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	ZOLOFT	sertraline hydrochloride	CONCENTRATE;ORAL	020990-001	Dec 7, 1999	AA	RX	Yes	Yes
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-002	Dec 30, 1991	AB	RX	Yes	Yes
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-005	Mar 6, 1996	AB	RX	Yes	No
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-001	Dec 30, 1991	AB	RX	Yes	No
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-004	Dec 30, 1991		DISCN	Yes	No
Viatris	ZOLOFT	sertraline hydrochloride	TABLET;ORAL	019839-003	Dec 30, 1991		DISCN	Yes	No

International Patents for ZOLOFT

See the table below for patents covering ZOLOFT around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	9006883
Ireland	802259
Estonia	200100221
U.S.S.R.	1014467	PROCESS FOR PREPARING DERIVATIVES OF CIS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHYLAMIINE OR THEIR SALTS
Australia	6389780
Japan	S5686137	ANTIDEPRESSANT DERIVATIVE OF CISS44PHENYLL1*2*3*44TETRAHYDROO11 NAPHTHALENEAMINE
Denmark	1129708

Supplementary Protection Certificates for ZOLOFT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0030081	SPC/GB93/048	United Kingdom		SPC/GB93/048, EXPIRES: 20051027
0030081	93C0073	Belgium		PRODUCT NAME: SERTRALINI HYDROCHLORID; NAT. REG.: 241 IS 30 F 19901119; FIRST REG.: GB PL 0057/03 19901119

Investment Scenario and Fundamentals Analysis of ZOLOFT (Sertraline)

Last updated: February 20, 2026

What is ZOLOFT and its market position?

ZOLOFT (sertraline hydrochloride) is a selective serotonin reuptake inhibitor (SSRI) approved for depression, obsessive-compulsive disorder (OCD), panic disorder, and several other conditions. It is marketed globally by Pfizer.

• Brand Status: Widely prescribed, with a patent expired in many regions.
• Market Share: Historically significant in the SSRI class. In 2022, the global antidepressant market was valued at approximately $17 billion, with ZOLOFT holding about 10-15% of the SSRI segment before generic entry (IQVIA, 2022).

What are the key fundamentals influencing investment prospects?

Patent and generic landscape

• Patent Timeline: The original patent expired in 2006 in the U.S., leading to generic competition.
• Current Market Dynamics: Off-patent status means Pfizer faces generic price erosion. Top competitors include fluoxetine (Prozac), escitalopram (Lexapro), and sertraline generics.
• Implications: Revenue from ZOLOFT has declined markedly since patent expiry due to generic substitution.

Regulatory and approval considerations

• FDA Status: ZOLOFT remains FDA-approved for multiple indications.
• Biosimilar or alternative formulations: No biosimilars; ongoing formulations and delivery methods are unchanged.

Revenue and sales data

Year	Approximate Sales (USD millions)	Notes
2010	1,500	Peak sales before patent expiry
2015	600	Continued decline post-generics
2020	300	Further erosion, primarily in mature markets
2022	200	Stabilization in some markets; decline persists

Revenue outlook

• Future revenue: Likely to decline further due to generics, with minimal growth prospects. Estimated annual sales expected to stabilize around USD 150-200 million in mature markets, with potential slight decline.

Competitive landscape

• Market share erosion: Generic SSRI alternatives capture recent prescriptions.
• Pricing pressures: Price erosion due to competition reduces profit margins.

R&D pipeline and lifecycle management

• No new formulations or indications have been prominently developed for ZOLOFT in recent years.
• Pfizer has shifted focus to newer antidepressants like vortioxetine and other mental health agents.

Financial health and investment considerations

• Revenue decline impact: Reduced revenue affects profitability.
• Cost structure: Operating costs related to manufacturing and marketing are likely stable but less impactful on overall profitability due to low revenues.
• Strategic options: Potential divestiture, licensing, or repositioning unlikely given the product’s mature status.

What are the key risks?

• Continued revenue erosion due to generics.
• Regulatory pressures or litigation costs.
• Limited near-term growth potential unless new indications or formulations are developed.
• Competitive market with numerous generic alternatives.

What opportunities exist for investment?

• Legacy brand stabilization: Some markets still show incremental prescriptions.
• Potential licensing or partnership for newer formulations outside developed markets.
• Portfolio realignment by Pfizer reducing exposure to low-growth assets.

Summary of valuation and investment considerations

• Historical valuation: ZOLOFT has low or no residual patent value; current valuation primarily reflects steady decline.
• Growth prospects: Marginal; primarily declines driven by generics.
• Strategic fit: Limited for growth-focused portfolios, relevant only for entities seeking legacy antidepressant assets.

Key Takeaways

• ZOLOFT's patent expiry in the mid-2000s led to a sharp decline in sales due to generic competition.
• The drug's market share diminishes annually, with projected revenues remaining in low hundreds of millions USD.
• No recent development of new indications or formulations limits future growth.
• Its value remains primarily from remaining mature markets, where prescriptions taper.
• Investors should regard ZOLOFT as a declining asset with minimal upside absent new patent protections or indications.

FAQs

1. Are there ongoing patent litigations or exclusivity rights for ZOLOFT? No. The original patents have expired globally, with no active exclusivity rights remaining.

2. Can ZOLOFT be repositioned for new indications? No, currently no approved new indications or formulations are under development for ZOLOFT.

3. What is the primary competition for ZOLOFT? Generic SSRIs such as escitalopram, fluoxetine, and newer antidepressants like vortioxetine.

4. What are the key factors influencing its future sales? Patent expirations, generic pricing, prescription trends for SSRIs, and market penetration in emerging markets.

5. Is ZOLOFT a viable acquisition target for generics manufacturers? Unlikely. It is already off-patent, with minimal remaining sales and low profit margins.

---

Sources:

[1] IQVIA. (2022). Global Prescription Market Reports.
[2] Pfizer. (2022). Annual Report.
[3] FDA. (2006). ZOLOFT (Sertraline Hydrochloride) Approval and Labeling.